Xilio Development Operating Income Over Time
| XLO Stock | USD 0.52 0.03 5.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Xilio Development Performance and Xilio Development Correlation. Will Biotechnology sector continue expanding? Could Xilio diversify its offerings? Factors like these will boost the valuation of Xilio Development. Anticipated expansion of Xilio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xilio Development data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 7.425 | Return On Assets | Return On Equity |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Xilio Development's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Xilio Development and related stocks such as PDS Biotechnology Corp, Actinium Pharmaceuticals, and Tempest Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.5 M) | (13.2 M) | (26.5 M) | (39.5 M) | (52 M) | (43.1 M) | (15.5 M) | (14.9 M) | (21.4 M) | (41.7 M) | (43 M) | (36.3 M) | (32.7 M) | (34.3 M) |
| ATNM | (17.5 K) | (10 K) | (7.9 M) | (6.6 M) | (22.5 M) | (24.8 M) | (26.8 M) | (26.9 M) | (23.8 M) | (22.1 M) | (22.4 M) | (25 M) | (34.1 M) | (51.9 M) | (42.1 M) | (37.9 M) | (36 M) |
| TPST | (2.6 M) | (2.6 M) | (13.5 M) | (29.1 M) | (47.9 M) | (72 M) | (81 M) | (20.5 M) | (23.1 M) | (45.4 M) | (19.3 M) | (27 M) | (34.6 M) | (29.2 M) | (42 M) | (37.8 M) | (39.7 M) |
| OKUR | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (39.8 M) | (29.8 M) | (36.9 M) | (54.4 M) | (48.9 M) | (51.4 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.7 M) | (24.7 M) | (37.3 M) | (43 M) | (54.7 M) | (71.2 M) | (111.4 M) | (90.6 M) | (81.5 M) | (77.5 M) |
| SKYE | 4.1 K | 4.1 K | 4.1 K | (7.2 K) | (2.7 M) | (4.3 M) | (4.5 M) | (3.9 M) | (4.7 M) | (6.6 M) | (6.3 M) | (7.8 M) | (18.3 M) | (34.7 M) | (30.2 M) | (27.2 M) | (25.8 M) |
| TVRD | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | (89.1 M) | (87.5 M) | (121.5 M) | (55.8 M) | (50.2 M) | (52.7 M) |
| ALGS | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (54 M) | (97.8 M) | (128.3 M) | (97.6 M) | (88.1 M) | (89.2 M) | (80.2 M) | (84.3 M) |
Xilio Development and related stocks such as PDS Biotechnology Corp, Actinium Pharmaceuticals, and Tempest Therapeutics Operating Income description
Operating Income is the amount of profit realized from Xilio Development operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Xilio Development is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Xilio Development | XLO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 828 Winter Street, |
| Exchange | NASDAQ Exchange |
USD 0.5216
Check out Xilio Development Performance and Xilio Development Correlation. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Xilio Development technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.